Wuxi biologics announces research service agreement with biontech on discovering investigational monoclonal antibodies for developing next-generation therapeutic product candidates

Shanghai , jan. 10, 2024 /prnewswire/ -- wuxi biologics ("wuxi bio") (2269. hk), a leading global contract research, development, and manufacturing organization (crdmo), today announced that its research service unit (r in crdmo) has signed a research service agreement with biontech se (nasdaq: bntx, "biontech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
BNTX Ratings Summary
BNTX Quant Ranking